BioTuesdays
Markets

Stifel cuts Acorda Therapeutics PT to $1 from $2.50

Stifel reduced its price target for Acorda Therapeutics (NASDAQ:ACOR) to $1 from $2.50 and maintained its “hold” rating, citing lower than expected first quarter revenue for its Inbrija inhaled formulation of levodopa...

May 6, 2020
Neuronetics Logo
Markets

WB cuts Neuronetics to market perform

William Blair downgraded Neuronetics (NASDAQ:STIM) to “market perform,” citing added uncertainty from COVID-19 headwinds and a commercial restructuring. The stock was quoted at $2.20, down 16 cents, in afternoon trading...

May 5, 2020
Cutera Logo
Markets

Stifel ups Cutera to buy from hold; PT $26

Stifel upgraded Cutera (NASDAQ:CUTR) to “buy” from “hold” with a $26 price target, citing a solid product pipeline, compelling valuation and a recently strengthened balance sheet. The stock closed at $12.90 on May 4...

May 5, 2020
PolarityTE Logo
Markets

HCW cuts PolarityTE to neutral and removes PT

H.C. Wainwright downgraded PolarityTE (NASDAQ:PTE) to “neutral” from “buy” and removed its price target, citing the clinical and regulatory risk from a strategy shift for its wound closure product, SkinTE. The stock...

May 4, 2020
Keros Therapeutics Logo
Markets

Analysts start Keros Therapeutics at buy, OP

Analysts for H.C. Wainwright and SVB Leerink launched coverage of Keros Therapeutics (NASDAQ:KROS) with “buy” and “outperform” ratings, respectively, citing Keros’ pipeline and platform differentiation. HCW analyst...

May 4, 2020
Xenetic Biosciences Logo
Markets

HCW starts Xenetic Biosciences at buy; PT $2

H.C. Wainwright initiated coverage of Xenetic Biosciences (NASDAQ:XBIO) with a “buy” rating and price target of $2. The stock closed at 86 cents on May 1. The main focus of the company is development of XCART, a CAR-T...

May 4, 2020
Axcella Logo
Markets

BTIG starts Axcella Health at buy; PT $10

BTIG launched coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $10 price target. The stock closed at $4.66 on April 30. “We view Axcella’s calculated approach to correcting metabolic diseases with...

May 1, 2020
Mersana Therapeutics Logo
Markets

BTIG starts Mersana Therapeutics at buy; PT $14

BTIG launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with a “buy” rating and $14 price target. The stock closed at $9.36 on April 28. Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer...

April 29, 2020
zentalis logo
Markets

SVB Leerink starts Zentalis Pharma at OP; PT $45

SVB Leerink initiated coverage of Zentalis Pharmaceuticals (NASDAQ:ZNTL) with an “outperform” rating and $45 price target. The stock closed at $31.76 on April 27. Zentalis’ lead compound is an oral selective estrogen...

April 28, 2020
Avadel Logo
Markets

Ladenburg ups Avadel Pharma PT to $20 from $14

Ladenburg Thalmann raised its price target for Avadel Pharmaceuticals (NASDAQ:AVDL) to $20 from $14 after the company posted positive topline Phase 3 results for FT218, a once nightly formulation of Micropump controlled...

April 28, 2020
Salarius Pharmaceuticals
Markets

Ladenburg starts Salarius Pharma at buy; PT $3.80

Ladenburg Thalmann launched coverage of Salarius Pharmaceuticals (NASDAQ:SLRX) with a “buy” rating and price target of $3.80. The stock closed at 63 cents on April 24. Salarius obtained a NASDAQ listing through a...

April 27, 2020
Centogene Logo
Markets

BTIG ups Centogene PT to $23 from $18

BTIG raised its price target for Centogene (NASDAQ:CNTG) to $23 from $18, citing a “solid execution” in its pharma and diagnostics segments in 2019. The stock closed at $18.69 on April 23. Analyst Sung Ji Nam writes...

April 24, 2020
Radius Health Logo
Markets

Stifel starts Radius Health at hold; PT $20

Stifel initiated coverage of Radius Health (NASDAQ:RDUS) with a “hold” rating and $20 target price. The stock closed at $17.18, up $1.43, on April 23. Analyst Annabel Samimy writes that Radius established a solid...

April 24, 2020
Interpace Biosciences Logo
Markets

AGP cuts Interpace Biosciences PT to $9.25

Alliance Global Partners lowered its price target for Interpace Biosciences (NASDAQ:IDXG) to $9.25 from a reverse split-adjusted $21, but maintained its “buy” rating, after the company posted fourth quarter...

April 24, 2020
Cutera Logo
Markets

Piper starts Cutera at OW; PT $18

Piper Sandler launched coverage of Cutera (NASDAQ:CUTR) with an “overweight” rating and $18 price target. The stock closed at $11.36 on April 21. Cutera is an aesthetics provider with technologies that will perform a...

April 22, 2020
Bicycle Therapeutics Logo
Markets

HCW starts Bicycle Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $25 price target. The stock finished at $14.66 on April 17. The company is focused on bicycles, which are synthetic, short...

April 20, 2020
Medicure
Markets

Mackie cuts Medicure PT to $2.80 from $6.50

Mackie Research slashed its price target for Medicure (TSXV:MPH) to $2.80 from $6.50, and maintained a “hold” rating, citing highly lowered revenue estimates. The stock closed at $2.41 on April 15. Analyst Andre Uddin...

April 16, 2020
Arcus Biosciences
Markets

BTIG ups Arcus Biosciences PT to $34 from $20

BTIG raised its price target for Arcus Biosciences (NYSE:RCUS) to $34 from $20, citing investors meetings with Arcus management that “reinforced careful development of important assets.” The stock closed at $15.58 on...

April 16, 2020